论文部分内容阅读
目的探讨血清中人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原-125(carbohydrate antigen 125,CA125)对卵巢恶性肿瘤的诊断价值。方法测定123例女性血清标本,其中卵巢恶性肿瘤34例,卵巢良性疾病39例,健康体检女性50例,用酶联免疫分析法(enzyme-linked immunosorbentassay,ELISA)和电化学发光法(electrochemiluminescence immunoassay,ECLIA)分别检测血清HE4和CA125水平。结果卵巢恶性肿瘤组血清HE4和CA125水平明显高于其他两组,差异有统计学意义(P<0.05);卵巢良性疾病组和健康对照组HE4比较差异无统计学意义(P>0.05)。以卵巢良性疾病作参照,单独检测血清HE4水平对卵巢恶性肿瘤诊断的敏感性为61.8%,低于单独检测CA125的73.5%;但特异性96.6%,高于CA125的80.9%。以二者其中之一高于参考值即视为阳性,联合检测血清HE4和CA125水平对卵巢恶性肿瘤诊断的敏感性94.1%,特异性80.9%,阴性预测值97.3%。结论检测血清HE4和CA125水平可明显提高卵巢恶性肿瘤诊断的准确率,并有助于卵巢良、恶性疾病的鉴别诊断。
Objective To investigate the diagnostic value of serum human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) in ovarian cancer. Methods Serum samples of 123 women were determined. Among them, 34 were ovarian malignant tumors, 39 were ovarian benign diseases and 50 were physical examinations. The serum levels were determined by enzyme-linked immunosorbentassay (ELISA) and electrochemiluminescence immunoassay ECLIA) were detected serum HE4 and CA125 levels. Results The serum levels of HE4 and CA125 in ovarian cancer group were significantly higher than those in the other two groups (P <0.05). There was no significant difference in HE4 between benign ovarian disease group and healthy control group (P> 0.05). To benign ovarian disease as a reference, the detection of serum HE4 levels alone was 61.8% sensitive to the diagnosis of ovarian cancer, lower than 73.5% of CA125 alone; but the specificity was 96.6%, higher than that of CA125 80.9%. The positive rate of serum HE4 and CA125 in combined detection of ovarian cancer was 94.1%, specificity 80.9%, and negative predictive value 97.3%. Conclusion Detection of serum HE4 and CA125 levels can significantly improve the diagnostic accuracy of ovarian cancer and contribute to the differential diagnosis of benign and malignant ovarian disease.